Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
13.31
-0.46 (-3.34%)
At close: Mar 3, 2026, 4:00 PM EST
13.24
-0.07 (-0.53%)
After-hours: Mar 3, 2026, 6:42 PM EST
Amneal Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Amneal Pharmaceuticals stock have an average target of 14.75, with a low estimate of 13 and a high estimate of 17. The average target predicts an increase of 10.82% from the current stock price of 13.31.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Amneal Pharmaceuticals stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Buy | 3 | 3 | 4 | 4 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $15 → $17 | Strong Buy | Maintains | $15 → $17 | +27.72% | Mar 2, 2026 |
| Barclays | Barclays | Buy Initiates $15 | Buy | Initiates | $15 | +12.70% | Dec 9, 2025 |
| Piper Sandler | Piper Sandler | Buy Reiterates $11 → $13 | Buy | Reiterates | $11 → $13 | -2.33% | Oct 31, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $12 → $14 | Buy | Maintains | $12 → $14 | +5.18% | Sep 16, 2025 |
| Barclays | Barclays | Buy Maintains $10 → $11 | Buy | Maintains | $10 → $11 | -17.36% | Mar 3, 2025 |
Financial Forecast
Revenue This Year
3.21B
from 3.02B
Increased by 6.40%
Revenue Next Year
3.42B
from 3.21B
Increased by 6.54%
EPS This Year
0.98
from 0.22
Increased by 343.51%
EPS Next Year
1.18
from 0.98
Increased by 20.74%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 3.4B | 3.7B | |
| Avg | 3.2B | 3.4B | |
| Low | 3.0B | 3.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 11.4% | 14.2% | |
| Avg | 6.4% | 6.5% | |
| Low | 0.6% | -0.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.05 | 1.28 | |
| Avg | 0.98 | 1.18 | |
| Low | 0.85 | 1.09 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 377.3% | 31.3% | |
| Avg | 343.5% | 20.7% | |
| Low | 284.4% | 11.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.